Barclays prefers Sonova as European hearing-aid recovery continues
BUZZ-Barclays prefers Sonova as European hearing-aid recovery continues ** Barclays said its latest US audiologist survey points to improving sentiment and a continued recovery in the hearing-aid market
** "Market recovery expected to persist although we see this as increasingly in the price and remain selective," the broker says
** It upgrades Swiss hearing-aid maker Sonova SOON.S to "overweight" from "underweight", expecting around 200 basis points of market-share gains and citing strong differentiation from its Phonak EON launch
** It downgrades GN Store Nord GN.CO to "equal weight" from "overweight", saying much of the recovery story is already reflected in the shares after a 32% rally over the last three months
** Barclays keeps Demant DEMANT.CO and Amplifon AMPF.MI at "equal weight", citing expected market-share losses for Demant and execution risks linked to Amplifon's integration of GN Hearing ** Including the session's moves, Sonova shares are up about 41% YTD, Demant is up 60%, GN up 9% and Amplifon down 17%
(Reporting by Kira Britten)
Recent news on Demant A/S
See all newsBarclays prefers Sonova as European hearing-aid recovery continues
Sonova raises full-year forecasts on market share gains, product launches (updated)
Jefferies moves Demant, Sonova to 'hold,' sees hearing-aid sector rally maturing
Europe Research Roundup: BAT, Imperial Brands, Kingfisher
Europe Research Roundup: Asos, Erste Group, SCHOTT pharma